Biocon Limited — Investor Meet, 11-08-2026: Analysts/Institutional Investor Meet/Con. Call Updates

Biocon's Q1 FY27 shows strong group revenue up 10%, with Biopharma driving (+17%). Biosimilars grew 16% to INR 2,855 Cr, while Generics jumped 21% with improved 7% EBITDA margin. Net profit soared 245% to INR 145 Cr, interest costs down 23%. Management is confident post-integration, focusing on profitable growth & cash flow. New launches like Aflibercept in the US & expanded insulin production in Malaysia are key for H2 biosimilar momentum. Q&A clarified generics growth, biosimilar pipeline, and debt strategy. Overall tone: confident for upcoming performance.